Currently, the choice of the treatment for patients with advanced NSCLC is based on the integrated evaluation of some parameters: histology (squamous versus non-squamous); presence of driver molecular alterations (sensitizing mutations of EGFR and/or BRAF, and rearrangements of ALK and/or ROS1 and/or NTRK); PD-L1 expression level; patient clinical characteristics such as age, performance status (PS) and comorbidities. Here, EGFR is linked to non-small cell lung carcinoma.